Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion to Raise up to $31.5M in Equity Financing

NEW YORK (GenomeWeb News) – Vermillion today said that it has inked an equity investment deal with certain investors to purchase up to $31.5 million of the firm's stock.

The Austin, Texas-based molecular diagnostics firm said that Oracle Investment Management, Jack Schuler, Matthew Strobeck, and other investors have agreed to make an initial investment in the company by purchasing 8 million shares of Vermillion common stock.

Once the transaction closes, the investors will receive a total of 12.5 million warrants with a strike price of $1.46. If the warrants are exercised, Vermillion would receive an additional $18.3 million in proceeds.

The firm said it would use the funds to support efforts aimed at increasing sales and improving reimbursement for its OVA1 test, which helps differentiate benign from malignant ovarian masses. It also said that the proceeds would help the firm expand its commercial opportunities in new markets and advance one or more next-generation ovarian cancer diagnostic tests.

Schuler, who is a former president and COO of Abbott Laboratories, is a co-founder of investment firm Crabtree Partners. Last year, he was part of an investment group that agreed to make an equity investment of up to $35 million in Accelr8 Diagnostics, and he now sits on that company's board of directors. He also is on the board of Quidel and previously served as chairman of the board of Ventana Medical Systems.

The equity investment comes about a month and a half after a dissident shareholder, Robert Goggin, was elected to Vermillion's board of directors.

Vermillion is scheduled to release its first-quarter financial results next week.

In Thursday morning trade on the Nasdaq, Vermillion's shares were up 20 percent at $1.75.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.